Homologous recombination deficiency in triple negative breast cancer

The Breast : Official Journal of the European Society of Mastology
Carmen BelliGiuseppe Curigliano

Abstract

Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9-12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10-20% of TNBC patients while somatic mutations occur in 3-5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.

Citations

Aug 14, 2020·Frontiers of Medicine·Hongnan Mo, Binghe Xu
Feb 9, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Juan JinXichun Hu
Jul 10, 2021·Signal Transduction and Targeted Therapy·Ruixue Huang, Ping-Kun Zhou
Aug 15, 2021·Journal for Immunotherapy of Cancer·Leisha A EmensJennifer K Litton
Aug 31, 2021·Current Breast Cancer Reports·Jodi A KagiharaJennifer R Diamond
Oct 13, 2021·Molecular Cancer Therapeutics·Jiaojiao DengMelanie Hayden Gephart
Jan 6, 2022·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Aiko SuetaYutaka Yamamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.